2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

Abstract

The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials.

Key words

neuroblastoma - ganglioneuroma - childhood cancer - treatment recommendations

Schlüsselwörter

Neuroblastom - Ganglioneurom - Behandlungsempfehlungen - Kind

• References

• 1 Adkins ES, Sawin R, Gerbing RB. et al. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg 2004; 39: 931-936
• 2 Agarwal S, Lakoma A, Chen Z. et al. G-CSF promotes neuroblastoma tumorigenicity and metastasis via STAT3-dependent cancer stem cell activation. Cancer Res 2015; 75: 2566-2579
• 3 Armstrong MB, Schumacher KR, Mody R. et al. Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 2008; 7: 135-145
• 4 Atkin KL, Ditchfield MR. The role of whole-body MRI in pediatric oncology. J Pediatr Hematol Oncol 2014; 36: 342-352
• 5 Attiyeh EF, London WB, Mosse YP. et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-2253
• 6 Bagatell R, London WB, Wagner LM. et al. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2010; 29: 208-213
• 7 Beiske K, Burchill SA, Cheung IY. et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 2009; 100: 1627-1637
• 8 Benz-Bohm G, Hero B, Gossmann A. et al. Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary?. Eur J Radiol 2010; 74: e1-e5
• 9 Berthold F, Boos J, Burdach S. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649-658
• 10 Berthold F, Hero B. Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 2000; 59: 1261-1277
• 11 Bertolini P, Lassalle M, Mercier G. et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26: 649-655
• 12 Bhatti P, Veiga LH, Ronckers CM. et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010; 174: 741-752
• 13 Bierau J, van Gennip AH, Leen R. et al. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma. Cancer Chemother Pharmacol 2006; 57: 105-113
• 14 Blaney SM, Seibel NL, O'Brien M. et al. Phase I trial of docetaxel administered as a 1-h infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 1997; 15: 1538-1543
• 15 Boglino C, Martins AG, Ciprandi G. et al. Spinal cord vascular injuries following surgery of advanced thoracic neuroblastoma: an unusual catastrophic complication. Med Pediatr Oncol 1999; 32: 349-352
• 16 Brignole C, Marimpietri D, Pastorino F. et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 2006; 98: 1142-1157
• 17 Brisse HJ, McCarville MB, Granata C. et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261: 243-257
• 18 Brodeur GM, Pritchard J, Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477
• 19 Brodeur GM, Seeger RC, Schwab M. et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124
• 20 Cai JY, Tang YJ, Jiang LM. et al. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma. Pediatr Blood Cancer 2007; 49: 952-957
• 21 Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995; 24: 215-221
• 22 Carrie C, Le Deley MC, Claude L. et al. The radiosensitization effect and toxicity of busulfan containing chemotherapy before radiotherapy for Ewing’s sarcomas. Strahlenther Onkol 2009; 185: 31
• 23 Casey DL, Kushner BH, Cheung NK. et al. Local control with 21-Gy radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2016; 96: S229
• 24 Castel V, Canete A, Navarro S. et al. Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results. Med Pediatr Oncol 2001; 37: 537-542
• 25 Castel V, Tovar JA, Costa E. et al. The role of surgery in stage IV neuroblastoma. J Pediatr Surg 2002; 37: 1574-1578
• 26 Cecchetto G, Mosseri V, De Bernardi B. et al. Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 2005; 23: 8483-8489
• 27 Cheung IY, Feng Y, Cheung NK. Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastoma. Pediatr Blood Cancer 2013; 60: E32-E34
• 28 Cheung NK, Heller G, Kushner BH. et al. Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate?. Med Pediatr Oncol 1999; 32: 84-87
• 29 Cheung NK, Kushner BH, Cheung IY. et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16: 3053-3060
• 30 Cheung NK, Kushner BH, LaQuaglia M. et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001; 36: 227-230
• 31 Cheung NK, Zhang J, Lu C. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 2012; 307: 1062-1071
• 32 Cohn SL, Pearson AD, London WB. et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27: 289-297
• 33 Coze C, Hartmann O, Michon J. et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 1997; 15: 3433-3440
• 34 Dahllof G, Borgstrom P, Lundell G. et al. Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 420-423
• 35 Danner-Koptik K, Kletzel M, Dilley KJ. Exostoses as a long-term sequela after pediatric hematopoietic progenitor cell transplantation: potential causes and increase risk of secondary malignancies from Ann & Robert H. Lurie Children's Hospital of Chicago. Biol Blood Marrow Transplant 19: 1267-1270
• 36 Danner-Koptik KE, Majhail NS, Brazauskas R. et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant 2013; 48: 363-368
• 37 De Bernardi B, Balwierz W, Bejent J. et al. Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer Lett 2005; 228: 283-299
• 38 De Bernardi B, Gambini C, Haupt R. et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol 2008; 26: 1710-1716
• 39 De Bernardi B, Gerrard M, Boni L. et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J Clin Oncol 2009; 27: 1034-1040
• 40 De Bernardi B, Nicolas B, Boni L. et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-1601
• 41 de Kraker J, Hoefnagel KA, Verschuur AC. et al. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. Eur J Cancer 2008; 44: 551-556
• 42 Decarolis B, Simon T, Krug B. et al. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. BMC Cancer 2016; 16: 542
• 43 DuBois SG, Chesler L, Groshen S. et al. Phase I study of vincristine, irinotecan, and (1)(3)(1)I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res 2012; 18: 2679-2686
• 44 Ducassou A, Gambart M, Munzer C. et al. Long-term side effects of radiotherapy for pediatric localized neuroblastoma: results from clinical trials NB90 and NB94. Strahlenther Onkol 2015; 191: 604-612
• 45 Duhem-Tonnelle V, Vinchon M, Defachelles AS. et al. Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases. Childs Nerv Syst 2006; 22: 500-505
• 46 Englum BR, Rialon KL, Speicher PJ. et al. Value of surgical resection in children with high-risk neuroblastoma. Pediatr Blood Cancer 2015; 62: 1529-1535
• 47 Erratum. Errata. Journal of Clinical Oncology 2014; 32: 1862-1863
• 48 Escobar MA, Grosfeld JL, Powell RL. et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006; 41: 377-381
• 49 Franzius C, Schmidt M, Hero B. et al. [Procedure guidelines for MIBG-scintigraphy in children]. Nuklearmedizin 2008; 47: 132-138
• 50 Frappaz D, Perol D, Michon J. et al. The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis. Br J Cancer 2002; 87: 1197-1203
• 51 French S, DuBois SG, Horn B. et al. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer 2013; 60: 879-884
• 52 Friedman DL, Whitton J, Leisenring W. et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083-1095
• 53 Fuchs J. The role of minimally invasive surgery in pediatric solid tumors. Pediatr Surg Int 2015; 31: 213-228
• 54 Garaventa A, Bellagamba O, Lo Piccolo MS. et al. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients. Br J Cancer 1999; 81: 1378-1384
• 55 Garaventa A, Gambini C, Villavecchia G. et al. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2003; 97: 1332-1338
• 56 Gatcombe HG, Marcus Jr. RB, Katzenstein HM. et al. Excellent local control from radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2009; 74: 1549-1554
• 57 Gaze MN, Boterberg T, Dieckmann K. et al. Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-risk Neuroblastoma Trial: a SIOPEN study. Int J Radiat Oncol Biol Phys 2013; 85: 170-174
• 58 Gaze MN, Chang YC, Flux GD. et al. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biother Radiopharm 2005; 20: 195-199
• 59 Geoerger B, Chisholm J, Le Deley MC. et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. Eur J Cancer 2011; 47: 230-238
• 60 Geoerger B, Doz F, Gentet JC. et al. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol 2008; 26: 4394-4400
• 61 Geoerger B, Hero B, Harms D. et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer 2001; 91: 1905-1913
• 62 George RE, Sanda T, Hanna M. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978
• 63 Geraci AP, de Csepel J, Shlasko E. et al. Ganglioneuroblastoma and ganglioneuroma in association with neurofibromatosis type I: report of three cases. J Child Neurol 1998; 13: 356-358
• 64 Gillis AM, Sutton E, Dewitt KD. et al. Long-term outcome and toxicities of intraoperative radiotherapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2007; 69: 858-864
• 65 Goo HW, Choi SH, Ghim T. et al. Whole-body MRI of paediatric malignant tumours: comparison with conventional oncological imaging methods. Pediatr Radiol 2005; 35: 766-773
• 66 Grewal S, Merchant T, Reymond R. et al. Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group. Pediatrics 2010; 125: e938-e950
• 67 Gurney JG, Tersak JM, Ness KK. et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children's Oncology Group. Pediatrics 2007; 120: e1229-e1236
• 68 Haas-Kogan DA, Swift PS, Selch M. et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56: 28-39
• 69 Hale GA, Arora M, Ahn KW. et al. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. Bone Marrow Transplant 2013; 48: 1056-1064
• 70 Handgretinger R, Anderson K, Lang P. et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995; 31A: 261-267
• 71 Hassan SF, Mathur S, Magliaro TJ. et al. Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children. J Pediatr Surg 2012; 47: 1261-1266
• 72 Hattangadi JA, Rombi B, Yock TI. et al. Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys 2012; 83: 1015-1022
• 73 Hawkins DS, Bradfield S, Whitlock JA. et al. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2006; 47: 790-794
• 74 Hero B, Simon T, Spitz R. et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26: 1504-1510
• 75 Hill-Kayser C, Tochner Z, Both S. et al. Proton versus photon radiation therapy for patients with high-risk neuroblastoma: the need for a customized approach. Pediatr Blood Cancer 2013; 60: 1606-1611
• 76 Hovi L, Saarinen UM, Siimes MA. Growth failure in children after total body irradiation preparative for bone marrow transplantation. Bone Marrow Transplant 1991; 8 (Suppl. 01) 10-13
• 77 Hsu WM, Jen YM, Lee H. et al. The influence of biologic factors on the surgical decision in advanced neuroblastoma. Ann Surg Oncol 2006; 13: 238-244
• 78 Irtan S, Brisse HJ, Minard-Colin V. et al. Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and image-defined risk factors. Pediatr Blood Cancer 2014;
• 79 Iwanaka T, Arai M, Ito M. et al. Surgical treatment for abdominal neuroblastoma in the laparoscopic era. Surg Endosc 2001; 15: 751-754
• 80 Jarzembowski JA, Lal DR, Shimada H. Re: Needle core vs open biopsy for diagnosis of intermediate- and high-risk neuroblastoma in children. J Pediatr Surg 2012; 47: 2162-2163 author reply 2163-2165
• 81 Kaatsch P, Spix C. German Childhood Cancer Registry - Report 2013/14 (1980-2013). In: Mainz: Institute of Medical Biostatistics, Epidemiology, and Informatics IMBEI) at the Universtiy Center of the Johannes Gutenberg University; 2014
• 82 Kaneko M, Tsuchida Y, Mugishima H. et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002; 24: 613-621
• 83 Kanold J, Paillard C, Tchirkov A. et al. Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model. Bone Marrow Transplant 2008; 42 (Suppl. 02) S25-S30
• 84 Kasahara K, Nakagawa T, Kubota T. Neuronal loss and expression of neurotrophic factors in a model of rat chronic compressive spinal cord injury. Spine 2006; 31: 2059-2066
• 85 Kembhavi SA, Rangarajan V, Shah S. et al. Prospective observational study on diagnostic accuracy of whole-body MRI in solid small round cell tumours. Clin Radiol 2014; 69: 900-908
• 86 Kim ES, Agarwal S, Shohet JM. G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response. Cancer Res 2015; 75: 3992
• 87 Kiratli PO, Tuncel M, Bar-Sever Z. Nuclear Medicine in Pediatric and Adolescent Tumors. Semin Nucl Med 2016; 46: 308-323
• 88 Kirkpatrick AW, Roberts DJ, De Waele J. et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 2013; 39: 1190-1206
• 89 Klingebiel T, Bader P, Bares R. et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998; 34: 1398-1402
• 90 Koh CC, Sheu JC, Liang DC. et al. Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma. Pediatr Surg Int 2005; 21: 69-72
• 91 Kohler JA, Imeson J, Ellershaw C. et al. A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer 2000; 83: 1124-1127
• 92 Koivusalo AI, Pakarinen MP, Rintala RJ. et al. Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution. Surg Today 2014; 44: 517-525
• 93 Kong G, Hofman MS, Murray WK. et al. Initial experience with Gallium-68 DOTA-Octreotate PET/CT and peptide receptor radionuclide therapy for pediatric patients with refractory metastatic neuroblastoma. J Pediatr Hematol Oncol 2016; 38: 87-96
• 94 Kraal K, Blom T, Tytgat L. et al. Neuroblastoma with intraspinal extension: Health problems in long-term survivors. Pediatr Blood Cancer 2016; 63: 990-996
• 95 Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol 2003; 25: 601-605
• 96 Kreissman SG, Seeger RC, Matthay KK. et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncology 2013; 14: 999-1008
• 97 Kretschmar CS, Kletzel M, Murray K. et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 2004; 22: 4119-4126
• 98 Kroiss A, Putzer D, Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification. Eur J Nucl Med Mol Imaging 39: 543
• 99 Kroiss A, Putzer D, Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 38: 865-873
• 100 Kushner BH, Cheung NK, Kramer K. et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant 2001; 28: 551-556
• 101 Kushner BH, Kramer K, LaQuaglia MP. et al. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 2003; 41: 508-515
• 102 Kushner BH, Kramer K, LaQuaglia MP. et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004; 22: 4888-4892
• 103 Kushner BH, Kramer K, Modak S. et al. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 2006; 24: 5271-5276
• 104 Kushner BH, Kramer K, Modak S. et al. High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatr Blood Cancer 2011; 56: 403-408
• 105 Kushner BH, LaQuaglia MP, Bonilla MA. et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 1994; 12: 2607-2613
• 106 Kushner BH, Wolden S, LaQuaglia MP. et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001; 19: 2821-2828
• 107 La Quaglia MP, Kushner BH, Heller G. et al. Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994; 29: 1162-1165 discussion 1165-1166
• 108 La Quaglia MP, Kushner BH, Su W. et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 2004; 39: 412-417 discussion 412–417
• 109 Ladenstein R, Poetschger U, Gray J. et al. Toxicity and outcome of anti-GD2antibody ch14.18/CHO in front-line, high-risk patients with neuroblastoma: Final results of the phase III immunotherapy randomisation (HR-NBL1/SIOPEN trial). Abstract No: 10500. J Clin Oncol 2016; 34
• 110 Ladenstein R, Poetschger U, Pearson AD. et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 tria. Lancet Oncol 2017;
• 111 Ladenstein R, Potschger U, Hartman O. et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplant 2008; 41 (Suppl. 02) S118-S127
• 112 Ladenstein R, Valteau-Couanet D, Brock P. et al. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010; 28: 3516-3524
• 113 Lang P, Pfeiffer M, Muller I. et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006; 218: 321-326
• 114 Langler A, Christaras A, Abshagen K. et al. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood - a phase-II-study. Klin Padiatr 2002; 214: 153-156
• 115 Lassmann M, Biassoni L, Monsieurs M. et al. The new EANM paediatric dosage card. Eur J Nucl Med Mol Imaging 2007; 34: 796-798
• 116 Laverdiere C, Cheung NK, Kushner BH. et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45: 324-332
• 117 London WB, Frantz CN, Campbell LA. et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2010; 28: 3808-3815
• 118 Malempati S, Nicholson HS, Reid JM. et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 2007; 25: 1505-1511
• 119 Maris JM, Healy J, Park J. et al. G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Letter. Cancer Res 2015; 75: 3991
• 120 Mastrangelo S, Rufini V, Ruggiero A. et al. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of (1)(3)(1)I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatr Blood Cancer 56: 1032-1040
• 121 Matthay KK, DeSantes K, Hasegawa B. et al. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol 1998; 16: 229-236
• 122 Matthay KK, Quach A, Huberty J. et al. Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol 2009; 27: 1020-1025
• 123 Matthay KK, Reynolds CP, Seeger RC. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27: 1007-1013
• 124 Matthay KK, Shulkin B, Ladenstein R. et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102: 1319-1326
• 125 Matthay KK, Tan JC, Villablanca JG. et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 2006; 24: 500-506
• 126 Matthay KK, Villablanca JG, Seeger RC. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173
• 127 Matthay KK, Weiss B, Villablanca JG. et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 2012; 53: 1155-1163
• 128 Mazloom A, Louis CU, Nuchtern J. et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014; 90: 858-862
• 129 McGregor LM, Rao BN, Davidoff AM. et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer 2005; 104: 2837-2846
• 130 Melzer HI, Coppenrath E, Schmid I. et al. 1)(2)(3)I-MIBG scintigraphy/SPECT versus (1)(8)F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 1648-1658
• 131 Merchant TE. Clinical controversies: proton therapy for pediatric tumors. Semin Radiat Oncol 2013; 23: 97-108
• 132 Modak S, Cheung IY, Kushner BH. et al. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer 58: 469-471
• 133 Monclair T, Brodeur GM, Ambros PF. et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27: 298-303
• 134 Mosse YP, Deyell RJ, Berthold F. et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer 2014; 61: 627-635
• 135 Muller-Berghaus J, Kurowski C, Gharib M. et al. Artificial abdominal hernia for the treatment of hepatomegaly in a neonate with stage 4S neuroblastoma. Pediatr Hematol Oncol 1999; 16: 453-458
• 136 Nathan PC, Ness KK, Greenberg ML. et al. Health-related quality of life in adult survivors of childhood Wilms tumor or neuroblastoma: A report from the childhood cancer survivor study. Pediatr Blood Cancer 2007; 49: 704-715
• 137 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Dinutuximab for treating high-risk neuroblastoma [ID799]. Available from. https://www.nice.org.uk/guidance/GID-TAG507/documents/committee-papers-2
• 138 Oertel S, Niethammer AG, Krempien R. et al. Combination of external-beam radiotherapy with intraoperative electron-beam therapy is effective in incompletely resected pediatric malignancies. Int J Radiat Oncol Biol Phys 2006; 64: 235-241
• 139 Okamatsu C, London WB, Naranjo A. et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG. Pediatr Blood Cancer 2009; 53: 563-569
• 140 Olivier P, Colarinha P, Fettich J. et al. Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging 2003; 30: B45-B50
• 141 Oshiro Y, Mizumoto M, Okumura T. et al. Clinical results of proton beam therapy for advanced neuroblastoma. Radiat Oncol 2013; 8: 142
• 142 Pai Panandiker AS, Beltran C, Billups CA. et al. Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma. Pediatr Blood Cancer 2013; 60: 761-765
• 143 Pai Panandiker AS, McGregor L, Krasin MJ. et al. Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int J Radiat Oncol Biol Phys 2010; 76: 1161-1165
• 144 Park JR, Kreissman SG, London WB et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB). A Children's Oncology Group (COG) study. In: 2016
• 145 Park JR, Scott JR, Stewart CF. et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011; 29: 4351-4357
• 146 Park JR, Slattery J, Gooley T. et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. Med Pediatr Oncol 2000; 35: 719-723
• 147 Park JR, Villablanca JG, London WB. et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009; 52: 44-50
• 148 Pearson AD, Craft AW, Pinkerton CR. et al. High-dose rapid schedule chemotherapy for disseminated neuroblastoma. Eur J Cancer 1992; 28A: 1654-1659
• 149 Pearson AD, Pinkerton CR, Lewis IJ. et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008; 9: 247-256
• 150 Peinemann F, Tushabe DA, van Dalen EC. et al. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. Cochrane Database Syst Rev 2015; CD010774
• 151 Philip T, Ghalie R, Pinkerton R. et al. A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1987; 5: 941-950
• 152 Piccardo A, Lopci E, Conte M. et al. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 2012; 39: 57-71
• 153 Picco P, Garaventa A, Claudiani F. et al. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer 1995; 76: 1662-1664
• 154 Pinto NR, Applebaum MA, Volchenboum SL. et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015; 33: 3008-3017
• 155 Pritchard J, Cotterill SJ, Germond SM. et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005; 44: 348-357
• 156 Quach A, Ji L, Mishra V. et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011; 56: 191-201
• 157 Reid JM, Qu W, Safgren SL. et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004; 22: 2445-2451
• 158 Retrosi G, Bishay M, Kiely EM. et al. Morbidity after ganglioneuroma excision: is surgery necessary?. Eur J Pediatr Surg 2011; 21: 33-37
• 159 Riccardi A, Servidei T, Tornesello A. et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995; 31A: 494-499
• 160 Robbins JR, Krasin MJ, Pai Panandiker AS. et al. Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience. J Pediatr Surg 2010; 45: 678-686
• 161 Rubie H, Chisholm J, Defachelles AS. et al. Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: a joint Societe Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study. J Clin Oncol 2006; 24: 5259-5264
• 162 Rubie H, Geoerger B, Frappaz D. et al. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. Eur J Cancer 2010; 46: 2763-2770
• 163 Rubino C, Adjadj E, Guerin S. et al. Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 2003; 107: 791-796
• 164 Rufini V, Giordano A, Di Giuda D. et al. [123I]MIBG scintigraphy in neuroblastoma: a comparison between planar and SPECT imaging. Q J Nucl Med 1995; 39: 25-28
• 165 Salim A, Mullassery D, Pizer B. et al. Neuroblastoma: a 20-year experience in a UK regional centre. Pediatr Blood Cancer 2011; 57: 1254-1260
• 166 Scanga DR, Martin WH, Delbeke D. Value of FDG PET imaging in the management of patients with thyroid, neuroendocrine, and neural crest tumors. Clin Nucl Med 2004; 29: 86-90
• 167 Schmidt M, Hero B, Pfluger T et al. DGN Handlungsempfehlung (S1-Leitlinie) mIBG Szitigraphie bei Kindern, Stand 04/2014, AWMF-Registernummer 031-040. Available from: http://www.awmf.org/uploads/tx_szleitlinien/031-040l_S1_mIBG-Szintigraphie_bei_Kindern_04-2013.pdf
• 168 Schmidt M, Simon T, Hero B. et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006; 45: 145-151 quiz N139–140
• 169 Schwab M, Ellison J, Busch M. et al. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci USA 1984; 81: 4940-4944
• 170 Seddon BM, Cassoni AM, Galloway MJ. et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clin Oncol (R Coll Radiol) 2005; 17: 385-390
• 171 Sharp SE, Shulkin BL, Gelfand MJ. et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med 2009; 50: 1237-1243
• 172 Shimada H, Ambros IM, Dehner LP. et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-372
• 173 Siebert N, Eger C, Seidel D. et al. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs 2016;
• 174 Siegel MJ, Acharyya S, Hoffer FA. et al. Whole-body MR imaging for staging of malignant tumors in pediatric patients: results of the American College of Radiology Imaging Network 6660 Trial. Radiology 2013; 266: 599-609
• 175 Simon T, Hero B, Faldum A. et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011; 11: 21
• 176 Simon T, Haberle B, Hero B. et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31: 752-758
• 177 Simon T, Hero B, Benz-Bohm G. et al. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial. Pediatr Blood Cancer 2008; 50: 965-969
• 178 Simon T, Hero B, Bongartz R. et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease. Strahlenther Onkol 2006; 182: 389-394
• 179 Simon T, Hero B, Dupuis W. et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 2002; 214: 149-152
• 180 Simon T, Hero B, Faldum A. et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004; 22: 3549-3557
• 181 Simon T, Hero B, Hunneman DH. et al. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 2003; 39: 1899-1903
• 182 Simon T, Hero B, Volland R. et al. Improved long-term survival after myeloablative chemotherapy with autologous stem cell transplantation in high-risk neuroblastoma patients. Results of the NB97 Trial. Pediatric Blood & Cancer 2016; 63: S39
• 183 Simon T, Langler A, Berthold F. et al. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial. J Pediatr Hematol Oncol 2007; 29: 101-106
• 184 Simon T, Langler A, Harnischmacher U. et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol 2007; 133: 653-661
• 185 Simon T, Niemann CA, Hero B. et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012; 54: 347-352
• 186 Simon T, Spitz R, Faldum A. et al. New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 2004; 26: 791-796
• 187 Son MH, Kang ES, Kim DH. et al. Efficacy and toxicity of plerixafor for peripheral blood stem cell mobilization in children with high-risk neuroblastoma. Pediatr Blood Cancer 60: E57-E59
• 188 Sorrentino S, Gigliotti AR, Sementa AR. et al. Neuroblastoma in the adult: the Italian experience with 21 patients. J Pediatr Hematol Oncol 2014; 36: e499-e505
• 189 Spitz R, Hero B, Simon T. et al. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res 2006; 12: 3368-3373
• 190 Stutterheim J, Zappeij-Kannegieter L, Versteeg R. et al. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 2011; 47: 1193-1202
• 191 Sudbrock F, Schmidt M, Simon T. et al. Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2010; 37: 1279-1290
• 192 Sugito K, Kusafuka T, Hoshino M. et al. Intraoperative radiation therapy for advanced neuroblastoma: the problem of securing the IORT field. Pediatr Surg Int 2007; 23: 1203-1207
• 193 Toporski J, Garkavij M, Tennvall J. et al. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant 2009; 15: 1077-1085
• 194 Tsuchida Y, Yokoyama J, Kaneko M. et al. Therapeutic significance of surgery in advanced neuroblastoma: a report from the study group of Japan. J Pediatr Surg 1992; 27: 616-622
• 195 Tweddle DA, Pinkerton CR, Lewis IJ. et al. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Med Pediatr Oncol 2001; 36: 239-242
• 196 Valentijn LJ, Koster J, Zwijnenburg DA. et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet 2015; 47: 1411-1414
• 197 Valentiner U, Haane C, Nehmann N. et al. Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res 2009; 29: 1219-1225
• 198 Valteau-Couanet D, Michon J, Boneu A. et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005; 23: 532-540
• 199 van Santen HM, de Kraker J, van Eck BL. et al. Improved radiation protection of the thyroid gland with thyroxine, methimazole, and potassium iodide during diagnostic and therapeutic use of radiolabeled metaiodobenzylguanidine in children with neuroblastoma. Cancer 2003; 98: 389-396
• 200 Vassal G, Giammarile F, Brooks M. et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d'Oncologie Pediatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 2008; 44: 2453-2460
• 201 Vettenranta K, Mottonen M, Riikonen P. The use of plerixafor in harvesting autologous stem cells in the pediatric setting. Pediatr Blood Cancer 2012; 59: 197-198
• 202 von Allmen D, Grupp S, Diller L. et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg 2005; 40: 936-941
• 203 von Schweinitz D, Hero B, Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 2002; 12: 402-409
• 204 Wagner LM, Villablanca JG, Stewart CF. et al. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J Clin Oncol 2009; 27: 1290-1296
• 205 Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP. et al. Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs 2006; 17: 859-864
• 206 Yanik GA, Levine JE, Matthay KK. et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol 2002; 20: 2142-2149
• 207 Yeung F, Chung PH, Tam PK. et al. Is complete resection of high-risk stage IV neuroblastoma associated with better survival?. J Pediatr Surg 2015; 50: 2107-2111
• 208 Yu AL, Gilman AL, Ozkaynak MF. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363: 1324-1334
• 209 Yu AL, Uttenreuther-Fischer MM, Huang CS. et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998; 16: 2169-2180
• 210 Zeng Y, Fest S, Kunert R. et al. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 2005; 42: 1311-1319
• 211 Zwaveling S, Tytgat GA, van der Zee DC. et al. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95% tumour resection suffice?. Pediatr Surg Int 2012; 28: 953-959